Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: A pilot study

Dana D. Cummings, Harvey S. Singer, Madeline Krieger, Teresa L. Miller, E. Mark Mahone

Research output: Contribution to journalArticlepeer-review

79 Scopus citations


The objective of this study was to evaluate the neuropsychiatric effects of the alpha-2a adrenergic agonist guanfacine in children with Tourette syndrome (TS). Twenty-four children with TS participated in a 4-week, double-blind, placebo-controlled study of guanfacine. Tic severity, neuropsychologic functioning, and parent ratings of behavior were evaluated pre- and post-treatment. The sample had mild tic severity and subtle neuropsychologic dysfunction pretreatment. Post-treatment, patients receiving guanfacine were rated by parents as significantly improved (compared to placebo) on one measure of executive function (parent-rated metacognition). Improvement on tic severity, performance-based neuropsychologic measures, and all other parent ratings were not significantly better than placebo. At a moderate dose and short-term treatment duration, guanfacine did not provide significant neuropsychiatric benefits in this group of children with mild TS.

Original languageEnglish (US)
Pages (from-to)325-332
Number of pages8
JournalClinical neuropharmacology
Issue number6
StatePublished - Nov 2002


  • Attention-deficit hyperactivity disorder
  • Behavioral Rating Inventory of Executive Function
  • Executive function
  • Guanfacine
  • Rating scales
  • Tourette syndrome

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: A pilot study'. Together they form a unique fingerprint.

Cite this